• Effective Small-scale Production of Antibodies.

Laboratory Products

Effective Small-scale Production of Antibodies.

Jan 23 2007

Using a CELLine 350 cell culture system, supplied by Integra Biosciences AG, the Institute for Molecular Medicine & Experimental Immunology (IMMEI) (Bonn, Germany) has transformed the effectiveness of its small-scale antibody production.

Designed for ease-of-use the CELLine 350 utilises proprietary membrane technology to separate off the cultivation chamber with an upper semi-permeable membrane through which nutrient can diffuse and a lower one that allows gases to diffuse. Separate ports allow selective access to the upper nutrient supply chamber and the central cultivation chamber. This novel compartmentalised arrangement means that medium can be exchanged without influencing the function or growth of the cells and gases. Consequently, traditional cell growth limitations brought about by a lack of nutrients or the accumulation of metabolic waste can be overcome just as easily as oxygen deficiency. Such optimised conditions promote significant cell growth and lead to drastically increased cell densities.

Cells growing under the optimal conditions created in CELLine reach densities of 107 to 108 cells per ml and the concentration of expressed protein is typically 50 to 100 times above what is found in standard cell culture disposables. By combining high product concentration with recurring product collection, large amounts of highly concentrated proteins are routinely obtained in CELLine. In the case of monoclonal antibodies (MAb), average concentrations range from 1 to 2 mg/ml of MAb (in both CELLine 350 and the larger CELLine 1000) and monthly yields typically range from 100 to 250 mg (using a CELLine 1000).

The CELLine has been designed to bring considerable cost savings to cell cultivation. The novel bioreactor drastically reduces the need for high capital investments in cell culture instrumentation or handling large amounts of cell culture disposables in order to be able to obtain milligram amounts of a designated protein. High production yields together with a 90% reduction in media supplement requirements enable further cost and time-savings in downstream processing steps.

Digital Edition

ILM 49.5 July

July 2024

Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...

View all digital editions


ADLM 2024

Jul 28 2024 San Diego, CA USA

InaLab 2024

Jul 30 2024 Jakarta, Indonesia


Jul 31 2024 Chengdu, China

ACS National Meeting - Fall 2024

Aug 18 2024 Denver, CO, USA


Aug 25 2024 Copenhagen, Denmark

View all events